Prescribers who co-sign, counter-sign or rewrite a semaglutide prescription for patients they haven’t seen or assessed would be considered in breach of professional standards, say two provincial regulators.
Concern over potential drug shortages arose after a Texas-based doctor licensed in Nova Scotia wrote 17,000 prescriptions for Ozempic over three months, but for people living in the United States.